FDA Determines Regulatory Review Period for DEXILANT Patent Extension

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for DEXILANT, a medication previously known as KAPIDEX, in accordance with federal regulations and in response to patent extension applications submitted to the Department of Commerce.